• Contact/
  • Home/

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • Advent Life Sciences
  • Advent Life Sciences

Page 1 of 24

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10Next >End >>
16.05.2022Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Press Release

11.05.2022Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release

04.05.2022Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release

04.05.2022Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release

04.05.2022AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022

Press Release

03.05.2022Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Press Release

02.05.2022Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

Press Release

27.04.2022ARGÁ MEDTECH SHOWS PROMISE FOR NEW CARDIAC ABLATION TECHNOLOGY AT 2022 HEART RHYTHM SOCIETY ANNUAL MEETING

Press Release

25.04.2022Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens

Press Release

14.04.2022Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR

Press Release



  • Privacy Policy
  • Legal and Regulatory Matters

©2022 Advent Life Sciences